- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00444925
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
4 de março de 2015 atualizado por: Pfizer
12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
1712
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Ahaus, Alemanha, 41683
- Pfizer Investigational Site
-
Alzey, Alemanha, 55232
- Pfizer Investigational Site
-
Berlin, Alemanha, 10787
- Pfizer Investigational Site
-
Berlin, Alemanha, 13125
- Pfizer Investigational Site
-
Berlin, Alemanha, 13347
- Pfizer Investigational Site
-
Karlsruhe, Alemanha, 76199
- Pfizer Investigational Site
-
Krumbach, Alemanha, 86381
- Pfizer Investigational Site
-
Leipzig, Alemanha, 04109
- Pfizer Investigational Site
-
Leipzig, Alemanha, 04105
- Pfizer Investigational Site
-
Marburg, Alemanha, 35039
- Pfizer Investigational Site
-
Muelheim a.d. Ruhr, Alemanha, 45468
- Pfizer Investigational Site
-
Muenchen, Alemanha, 81241
- Pfizer Investigational Site
-
Muenchen, Alemanha, 81925
- Pfizer Investigational Site
-
Rosenheim, Alemanha, 83022
- Pfizer Investigational Site
-
-
-
-
BA
-
Salvador, BA, Brasil, 40420-000
- Pfizer Investigational Site
-
-
RJ
-
Rio de Janeiro, RJ, Brasil, CEP 20551-030
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, Brasil, 90020-090
- Pfizer Investigational Site
-
Porto Alegre, RS, Brasil, 90470-340
- Pfizer Investigational Site
-
-
SP
-
Campinas, SP, Brasil, 13084-882
- Pfizer Investigational Site
-
São Paulo, SP, Brasil, 04262-000
- Pfizer Investigational Site
-
São Paulo, SP, Brasil, 04039-901
- Pfizer Investigational Site
-
-
-
-
-
Antwerpen, Bélgica, 2020
- Pfizer Investigational Site
-
Bruxelles, Bélgica, 1070
- Pfizer Investigational Site
-
Kortrijk, Bélgica, 8500
- Pfizer Investigational Site
-
Tessenderlo, Bélgica, 3980
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2V 4R6
- Pfizer Investigational Site
-
Edmonton, Alberta, Canadá, T5H 3V9
- Pfizer Investigational Site
-
-
British Columbia
-
Victoria, British Columbia, Canadá, V8V 3N1
- Pfizer Investigational Site
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá, E2L 3J8
- Pfizer Investigational Site
-
-
Ontario
-
Kitchener, Ontario, Canadá, N2N 2B9
- Pfizer Investigational Site
-
Toronto, Ontario, Canadá, M4N 3M5
- Pfizer Investigational Site
-
Toronto, Ontario, Canadá, M6A 3B5
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 1N8
- Pfizer Investigational Site
-
Montreal, Quebec, Canadá, H3S 1Z1
- Pfizer Investigational Site
-
Montréal, Quebec, Canadá, H2X 3J4
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Pfizer Investigational Site
-
-
-
-
-
Puerto Montt, Chile, 5480000
- Pfizer Investigational Site
-
Santiago, Chile
- Pfizer Investigational Site
-
-
VI Región
-
Rancagua, VI Región, Chile, 2820945
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Cingapura, 119074
- Pfizer Investigational Site
-
Singapore, Cingapura, 229899
- Pfizer Investigational Site
-
-
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colômbia
- Pfizer Investigational Site
-
Bogota, Cundinamarca, Colômbia
- Pfizer Investigational Site
-
-
-
-
-
Alajuela, Costa Rica
- Pfizer Investigational Site
-
Cartago, Costa Rica
- Pfizer Investigational Site
-
San Jose, Costa Rica
- Pfizer Investigational Site
-
-
-
-
-
Aalborg, Dinamarca, 9100
- Pfizer Investigational Site
-
Aarhus N, Dinamarca, 8200
- Pfizer Investigational Site
-
Glostrup, Dinamarca, 2600
- Pfizer Investigational Site
-
Herlev, Dinamarca, 2730
- Pfizer Investigational Site
-
Kolding, Dinamarca, 6000
- Pfizer Investigational Site
-
Nykoebing Falster, Dinamarca, 4800
- Pfizer Investigational Site
-
Roskilde, Dinamarca, 4000
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Espanha, 28046
- Pfizer Investigational Site
-
Valencia, Espanha, 46010
- Pfizer Investigational Site
-
-
Madrid
-
Getafe, Madrid, Espanha, 28905
- Pfizer Investigational Site
-
-
Vizcaya
-
Bilbao, Vizcaya, Espanha, 48013
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Homewood, Alabama, Estados Unidos, 35209
- Pfizer Investigational Site
-
Huntsville, Alabama, Estados Unidos, 35801
- Pfizer Investigational Site
-
Mobile, Alabama, Estados Unidos, 36608
- Pfizer Investigational Site
-
-
California
-
Carmichael, California, Estados Unidos, 95608
- Pfizer Investigational Site
-
Orangevale, California, Estados Unidos, 95662
- Pfizer Investigational Site
-
San Diego, California, Estados Unidos, 92103-6204
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Pfizer Investigational Site
-
-
Connecticut
-
Waterbury, Connecticut, Estados Unidos, 06708
- Pfizer Investigational Site
-
-
Florida
-
Miami, Florida, Estados Unidos, 33186
- Pfizer Investigational Site
-
Wellington, Florida, Estados Unidos, 33414
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Pfizer Investigational Site
-
-
Idaho
-
Coeur D Alene, Idaho, Estados Unidos, 83814
- Pfizer Investigational Site
-
Sandpoint, Idaho, Estados Unidos, 83864
- Pfizer Investigational Site
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Pfizer Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50266
- Pfizer Investigational Site
-
-
Kansas
-
Newton, Kansas, Estados Unidos, 67114
- Pfizer Investigational Site
-
-
Louisiana
-
Shrevport, Louisiana, Estados Unidos, 71106
- Pfizer Investigational Site
-
-
Massachusetts
-
Watertown, Massachusetts, Estados Unidos, 02472
- Pfizer Investigational Site
-
-
Minnesota
-
Chaska, Minnesota, Estados Unidos, 55318
- Pfizer Investigational Site
-
-
New Jersey
-
Lawrenceville, New Jersey, Estados Unidos, 08648
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Pfizer Investigational Site
-
-
New York
-
Garden City, New York, Estados Unidos, 11530
- Pfizer Investigational Site
-
Mineola, New York, Estados Unidos, 11501
- Pfizer Investigational Site
-
-
North Carolina
-
Burlington, North Carolina, Estados Unidos, 27215
- Pfizer Investigational Site
-
Concord, North Carolina, Estados Unidos, 28025
- Pfizer Investigational Site
-
Huntersville, North Carolina, Estados Unidos, 28078
- Pfizer Investigational Site
-
-
Ohio
-
Dayton, Ohio, Estados Unidos, 45439
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18106
- Pfizer Investigational Site
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213-3180
- Pfizer Investigational Site
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Pfizer Investigational Site
-
Columbia, South Carolina, Estados Unidos, 29201
- Pfizer Investigational Site
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Pfizer Investigational Site
-
Milan, Tennessee, Estados Unidos, 38358
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Estados Unidos, 77024
- Pfizer Investigational Site
-
-
Utah
-
Provo, Utah, Estados Unidos, 84604
- Pfizer Investigational Site
-
-
Virginia
-
Chesapeake, Virginia, Estados Unidos, 23320
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Pfizer Investigational Site
-
-
Wisconsin
-
Menomonee Falls, Wisconsin, Estados Unidos, 53051
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Federação Russa, 101000
- Pfizer Investigational Site
-
Moscow, Federação Russa, 115516
- Pfizer Investigational Site
-
Moscow, Federação Russa, 117815
- Pfizer Investigational Site
-
Rostov-on-Don, Federação Russa, 344022
- Pfizer Investigational Site
-
-
Russia
-
Moscow, Russia, Federação Russa, 105425
- Pfizer Investigational Site
-
St. Petersburg, Russia, Federação Russa
- Pfizer Investigational Site
-
-
-
-
-
Rio, Patras, Grécia, 26500
- Pfizer Investigational Site
-
Thessaloniki, Grécia, 56403
- Pfizer Investigational Site
-
-
Attiki
-
Athens, Attiki, Grécia, 10552
- Pfizer Investigational Site
-
-
Ipiros
-
Ioannina, Ipiros, Grécia, 45001
- Pfizer Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- Pfizer Investigational Site
-
Shatin, Hong Kong
- Pfizer Investigational Site
-
-
-
-
-
Debrecen, Hungria, 4026
- Pfizer Investigational Site
-
Nyiregyhaza, Hungria, 4400
- Pfizer Investigational Site
-
Szeged, Hungria, 6725
- Pfizer Investigational Site
-
Szentes, Hungria, 6600
- Pfizer Investigational Site
-
-
-
-
-
Latina, Itália, 04100
- Pfizer Investigational Site
-
Padova, Itália, 35128
- Pfizer Investigational Site
-
Siena, Itália, 53100
- Pfizer Investigational Site
-
-
-
-
-
Kuala Lumpur, Malásia, 59100
- Pfizer Investigational Site
-
-
Selangor
-
Batu Caves, Selangor, Malásia, 68100
- Pfizer Investigational Site
-
-
-
-
-
Bergen, Noruega, 5005
- Pfizer Investigational Site
-
Hamar, Noruega, 2317
- Pfizer Investigational Site
-
Lysaker, Noruega, 1366
- Pfizer Investigational Site
-
Oslo, Noruega, NO-0257
- Pfizer Investigational Site
-
Oslo, Noruega, 0264
- Pfizer Investigational Site
-
Sandnes, Noruega, 4313
- Pfizer Investigational Site
-
-
-
-
-
Lima, Peru, L27
- Pfizer Investigational Site
-
-
Lima
-
Surco, Lima, Peru, L33
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Polônia, 15-950
- Pfizer Investigational Site
-
Bydgoszcz, Polônia, 85-168
- Pfizer Investigational Site
-
Lodz, Polônia, 91-463
- Pfizer Investigational Site
-
Szczecin, Polônia, 70-11
- Pfizer Investigational Site
-
Warszawa, Polônia, 02-507
- Pfizer Investigational Site
-
-
-
-
-
Daegu, Republica da Coréia, 705-718
- Pfizer Investigational Site
-
Seoul, Republica da Coréia, 120-752
- Pfizer Investigational Site
-
Seoul, Republica da Coréia, 136-705
- Pfizer Investigational Site
-
Seoul, Republica da Coréia, 137-040
- Pfizer Investigational Site
-
Seoul, Republica da Coréia, 100-380
- Pfizer Investigational Site
-
-
Korea
-
Seoul, Korea, Republica da Coréia, 110-744
- Pfizer Investigational Site
-
-
-
-
-
Hradec Kralove, República Checa, 500 02
- Pfizer Investigational Site
-
Jablonec nad Nisou, República Checa, 466 60
- Pfizer Investigational Site
-
Jindrichuv Hradec, República Checa, 377 38
- Pfizer Investigational Site
-
Ostrava, República Checa, 708 52
- Pfizer Investigational Site
-
Praha 8, República Checa, 180 00
- Pfizer Investigational Site
-
-
-
-
-
Arad, Romênia, 310175
- Pfizer Investigational Site
-
Bucuresti, Romênia, 041345
- Pfizer Investigational Site
-
Bucuresti, Romênia, 050653
- Pfizer Investigational Site
-
Sibiu, Romênia, 550245
- Pfizer Investigational Site
-
Timisoara, Romênia, 300736
- Pfizer Investigational Site
-
-
-
-
-
Huskvarna, Suécia, 561 36
- Pfizer Investigational Site
-
Lulea, Suécia, 97180
- Pfizer Investigational Site
-
Malmo, Suécia, 205 02
- Pfizer Investigational Site
-
Skovde, Suécia, 541 30
- Pfizer Investigational Site
-
Stockholm, Suécia
- Pfizer Investigational Site
-
-
-
-
-
Frauenfeld, Suíça, CH-8500
- Pfizer Investigational Site
-
Luzern 16, Suíça, CH-6000
- Pfizer Investigational Site
-
-
-
-
-
Hualien, Taiwan, 970
- Pfizer Investigational Site
-
Taichung City, Taiwan, 40705
- Pfizer Investigational Site
-
Taipei, Taiwan, 100
- Pfizer Investigational Site
-
Taipei, Taiwan
- Pfizer Investigational Site
-
-
Kaohsiung
-
Niao-Sung Hsiang, Kaohsiung, Taiwan, 833
- Pfizer Investigational Site
-
-
-
-
-
Chernivtsi, Ucrânia, 58002
- Pfizer Investigational Site
-
Kharkiv, Ucrânia, 61037
- Pfizer Investigational Site
-
Kyiv, Ucrânia, 04053
- Pfizer Investigational Site
-
Odessa, Ucrânia, 65000
- Pfizer Investigational Site
-
Zaporizhzhia, Ucrânia, 69000
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, África do Sul, 8001
- Pfizer Investigational Site
-
Pretoria, África do Sul, 0083
- Pfizer Investigational Site
-
-
Free State
-
Bloemfontein, Free State, África do Sul, 9300
- Pfizer Investigational Site
-
-
Gauteng
-
Vosloorus, Gauteng, África do Sul, 1475
- Pfizer Investigational Site
-
-
Gauteng Province
-
Parktown, Gauteng Province, África do Sul, 2193
- Pfizer Investigational Site
-
-
Kwa Zulu Natal
-
Durban, Kwa Zulu Natal, África do Sul, 4001
- Pfizer Investigational Site
-
Pietermaritzburg, Kwa Zulu Natal, África do Sul, 3201
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Índia, 500 001
- Pfizer Investigational Site
-
Hyderabad, Andhra Pradesh, Índia, 500 082
- Pfizer Investigational Site
-
-
Karnataka
-
Bangalore, Karnataka, Índia, 560 034
- Pfizer Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Índia, 302 004
- Pfizer Investigational Site
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Índia, 632 004
- Pfizer Investigational Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Índia, 226003
- Pfizer Investigational Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency >= 8 per day and urgency urinary incontinence >=1 per day
Exclusion Criteria:
- Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Fesoterodina
Comprimidos
|
4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
|
|
Comparador de Placebo: Placebo
Tablets and capsules
|
once daily (OD)for 12 weeks
|
|
Comparador Ativo: Tolterodine
Capsules
|
4 mg once daily (OD) for 12 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).
Prazo: Baseline, Week 12
|
UUI per 24 hours: total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit.
USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change: mean at observation minus mean at baseline.
|
Baseline, Week 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 1 and Week 4.
Prazo: Baseline, Week 1, Week 4
|
UUI episodes per 24 hours calculated as total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4
|
|
Percent Change From Baseline of UUI Episodes Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
UUI episodes per 24 hours calculated as total number of micturitions with USS of 5 in diary.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as UUI episodes per 24 hours at observation divided by baseline number of UUI episodes per 24 hours, multiplied by 100.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Voided Volume Per Micturition.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Mean voided volume calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0 in the 3-day diary at that visit.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Micturitions Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
The mean number of micturitions was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit.
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Micturitions Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Mean number of nocturnal micturitions per 24 hours was calculated as the sum of all micturitions divided by the total number of diary days collected at that visit.
Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Percent change of nocturnal micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (ie, 100% *(Week 12 or 4 - baseline)/baseline). Nocturnal (Bedtime) was defined as the time the subject went to bed until he/she arose to start the next day.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Mean number urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as sum of all micturitions divided by total number of diary days collected at visit.
USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Urgency Episodes Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Percent change of urgency episodes (USS rating >= to 3 in diary) per 24 hours calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100.
USS: 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Mean number of severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours: sum of all micturitions divided by total number of diary days collected at that visit.
USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Percent change calculated as change in severe urgency episodes (USS rating >= to 4 in diary ) per 24 hours at that visit divided by the baseline number of severe urgency episodes per 24 hours, multiplied by 100.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Mean USS Rating Per Micturition Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Mean USS rating calculated as the sum of rating scores on USS per 24 hours divided by the mean number of micturitions per 24 hours at that visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Frequency-Urgency Sum (Formerly Known as Urinary Sensations Scale Sum in Protocol) Per 24 Hours.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Frequency-Urgency Sum rating per 24 hours calculated as mean rating scores on the USS multiplied by the mean number of micturitions per 24 hours at that visit.
USS is 5-item scale measuring urinary urgency; range is 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Change calculated as mean at observation minus mean at baseline.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Patient Perception of Bladder Condition (PPBC).
Prazo: Baseline, Week 1, Week, 4, Week 12
|
Number of subjects in 4-point category: >= to 2 points improvement [major improvement]; 1 point improvement [minor improvement]; no change; deterioration, based on PPBC score (rated on 6-point scale: 1=no problems at all; 6=many severe problems).
Score change: score at observation minus score at baseline; re-scaled to 4-point categorical variables.
|
Baseline, Week 1, Week, 4, Week 12
|
|
Change From Baseline in Urgency Perception Scale (UPS). UPS Equals Patient Perception of Urgency Scale (PPUS) in Protocol.
Prazo: Baseline, Week 1, Week 4, Week 12
|
Number of subjects in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing).
Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.
|
Baseline, Week 1, Week 4, Week 12
|
|
Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12 (End of Treatment).
Prazo: Baseline, Week 12
|
Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48.
Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/by raw score range * 100].
Higher transformed scores indicative of greater symptom bother.
Negative change in Symptom Bother score indicates improvement.
Change calculated as score at observation minus score at baseline.
|
Baseline, Week 12
|
|
Change From Baseline in OAB-q: Health Related Quality of Life (HRQL) at Week 12 (End of Treatment).
Prazo: Baseline, Week 12
|
HRQL domain and total raw score derived as sum of scores (6-point scale: 1=not at all/none of the time; 6=a very great deal/all of the time).
Transformed score (Total HRQL or domain)=[(Highest possible raw score-Actual total raw score)/Raw score range]x100.
Higher transformed scores indicative of better HRQL.
Positive change in HRQL scores indicates improvement.
Change: score at observation minus score at baseline.
|
Baseline, Week 12
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M. A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder. J Comp Eff Res. 2022 Sep;11(13):919-925. doi: 10.2217/cer-2022-0041. Epub 2022 Jul 26.
- Corcos J, Angulo JC, Garely AD, Carlsson M, Gong J, Guan Z; Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group. Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Curr Med Res Opin. 2011 May;27(5):1059-65. doi: 10.1185/03007995.2011.565044. Epub 2011 Mar 23.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de abril de 2007
Conclusão Primária (Real)
1 de julho de 2008
Conclusão do estudo (Real)
1 de julho de 2008
Datas de inscrição no estudo
Enviado pela primeira vez
6 de março de 2007
Enviado pela primeira vez que atendeu aos critérios de CQ
7 de março de 2007
Primeira postagem (Estimativa)
8 de março de 2007
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
24 de março de 2015
Última atualização enviada que atendeu aos critérios de controle de qualidade
4 de março de 2015
Última verificação
1 de março de 2015
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Urológicas
- Doenças da Bexiga Urinária
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Bexiga Urinária Hiperativa
- Efeitos Fisiológicos das Drogas
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Antagonistas Muscarínicos
- Antagonistas colinérgicos
- Agentes colinérgicos
- Agentes Urológicos
- Tartarato de Tolterodina
- Fesoterodina
Outros números de identificação do estudo
- A0221008
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .